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OBJECTIVE— The purpose of this study was to develop a model for assessing the 5-year risk
of developing type 2 diabetes from a panel of 64 circulating candidate biomarkers.
RESEARCH DESIGN AND METHODS— Subjects were selected from the Inter99
cohort, a longitudinal population-based study of6,600 Danes in a nested case-control design
with the primary outcome of 5-year conversion to type 2 diabetes. Nondiabetic subjects, aged
39 years, with BMI25 kg/m2 at baseline were selected. Baseline fasting serum samples from
160 individuals who developed type 2 diabetes and from 472 who did not were tested. An
ultrasensitive immunoassay was used to measure of 58 candidate biomarkers in multiple diabe-
tes-associated pathways, along with six routine clinical variables. Statistical learning methods
and permutation testing were used to select the most informative biomarkers. Risk model
performance was estimated using a validated bootstrap bias-correction procedure.
RESULTS— A model using six biomarkers (adiponectin, C-reactive protein, ferritin, inter-
leukin-2 receptor A, glucose, and insulin) was developed for assessing an individual’s 5-year risk
of developing type 2 diabetes. This model has a bootstrap-estimated area under the curve of 0.76,
which is greater than that for A1C, fasting plasma glucose, fasting serum insulin, BMI, sex-
adjusted waist circumference, a model using fasting glucose and insulin, and a noninvasive
clinical model.
CONCLUSIONS— A model incorporating six circulating biomarkers provides an objective
and quantitative estimate of the 5-year risk of developing type 2 diabetes, performs better than
single risk indicators and a noninvasive clinical model, and provides better stratification than
fasting plasma glucose alone.
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The prevalence of type 2 diabetes hasreached epidemic levels, affecting7% of the U.S. population, and
current epidemiological trends indicate
that the prevalence will continue to in-
crease dramatically (1). Several long-term
prospective clinical trials have shown that
interventions can delay or possibly pre-
vent the onset of type 2 diabetes in high-
risk individuals (2,3), underscoring the
importance of identifying individuals at
risk to begin interventions as early as pos-
sible and focus resources on those with
the highest risk.
The most commonly used method of
assessing risk of type 2 diabetes is mea-
suring fasting plasma glucose (FPG);
however, the specificity of this test is poor
(4,5). Although many individuals are
identified as having impaired fasting glu-
cose (IFG), their absolute risk of conver-
sion to diabetes is only 5–10% per year
(6). The oral glucose tolerance test
(OGTT) is more accurate for risk assess-
ment. However, it is rarely used in prac-
tice because it is unpleasant for the patient
and requires 2 h to perform. Another
challenge is that by the time glucose reg-
ulation is abnormal, the underlying dis-
ease has been progressing for many years,
and complications have already occurred
in a significant number of individuals (7).
Thus, the rationale of using one variable
to assess risk is questionable, when the
risk of harm actually varies based on a
range of variables and would be better as-
sessed using a multivariable individual-
ized risk score (8).
Several indexes using clinical infor-
mation and routine laboratory measure-
ments have been developed for assessing
type 2 diabetes risk (9–11). These have
never been widely adopted by physicians.
Given the limitations of the OGTT, FPG,
and indexes that the clinician must calcu-
late, it is clear that an improved method
for assessing type 2 diabetes risk, with a
convenient format for routine clinical use,
would enable physicians to accurately
evaluate more individuals.
The dysregulation of many biological
pathways precedes the development of
overt type 2 diabetes (12). Although
many studies have assessed whether levels
of a few molecules might predict future di-
abetes (13–15), none have quantitatively
measured a large number of molecules si-
multaneously in a sufficient number of
samples to robustly evaluate their utility
for risk assessment. We undertook a sys-
tematic analysis of many candidates in
pathways dysregulated in diabetes to
search for patterns of biomarkers with
more predictive power than individual bi-
omarkers or previously examined bi-
omarker combinations. For this analysis,
we selected 632 baseline samples from
the Inter99 Study and an ultrasensitive
immunoassay to measure many proteins
in small amounts of serum.
RESEARCH DESIGN AND
METHODS— The Inter99 cohort
consists of 61,301 subjects aged 30–60
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years from the Danish Civil Registration
System. Although this was a lifestyle in-
tervention trial for cardiovascular disease
(14), the 5-year rate of progression to type
2 diabetes observed in this study (3.4%)
was similar to other estimates of progres-
sion for this age-group (16). A sample of
13,016 was randomly selected; of these,
12,934 were eligible and invited for an
examination, and 6,784 (52.5%) at-
tended (17). Eligible individuals (n 
6,536) were reinvited after 5 years and
4,511 (69%) attended. Fasting blood
samples, lifestyle data, blood pressure,
waist circumference, plasma lipids, and
OGTT results were collected at baseline
and at 5-year time points. We defined an
“at-risk” subpopulation as those aged
39 years with BMI25 kg/m2 and free
of diabetes at baseline. Among these indi-
viduals, 174 progressed to type 2 diabetes
during the 5-year follow-up (converters),
and baseline samples were available for
160, whereas 2,872 did not progress
(nonconverters). Diagnosis of type 2 dia-
betes was defined by a 2-h plasma glucose
of 11.1 mmol/l in an OGTT or FPG of
7.0 mmol/l. Nonconverters (n  472)
were randomly selected in an 3:1 ratio
to converters.
Clinical and standard laboratory
measurements
Blood pressure was obtained and anthro-
pometric measurements, routine labora-
tory measures (FPG, insulin, and lipids),
and the OGTT were performed as de-
scribed previously (17). Serum was
stored at 19°C.
Candidate biomarker selection
Potential biomarkers were identified by
searching the PubMed database using
search terms relevant to the development
of diabetes. Of 260 candidate biomarkers
identified as being involved in pathways
associated with metabolic or cardiovascu-
lar disorders, obesity, cell death, or in-
flammatory response, we successfully
obtained assay reagents for 89. Data from
58 candidate biomarkers met our quality
control criteria, which required that re-
sults from 66% of the samples had to
fall within the assay’s linear dynamic
range.
Molecular assays
Sandwich immunoassays developed for
the 58 proteins typically used a monoclo-
nal capture antibody and a fluorescently
labeled detection antibody. Biomarker
candidates were measured using an ultra-
sensitive molecular counting technology
platform (Singulex, St. Louis, MO). De-
tails regarding assay reagents have been
described previously (18). In brief, la-
beled antibodies were detected with the
ZeptX system, in which liquid from each
well is pumped through an interrogation
space within a capillary flow cell. Laser
light (wavelength 650 nm) is directed
into the interrogation space, and the re-
sulting emission from each labeled anti-
body (wavelength 668 nm) is measured
via a confocal microscope with a photon
detector.
For biomarkers in the model, re-
agents were obtained from R&D Sys-
tems (Minneapolis, MN) individually
(monomeric adiponectin [ADIPOQ]) or
as DuoSet kits (interleukin-2 receptor A
[IL-2RA]) and from U.S. Biological
(Swampscott, MA) (C-reactive protein
[CRP] and ferritin heavy chain 1
[FTH1]). Detection antibodies for
ADIPOQ, CRP, and FTH1 were conju-
gated with Alexa Fluor 647 (Invitrogen,
Carlsbad, CA) according to the manu-
facturer’s instructions and purified by
ultrafiltration with Microcon YM-30
from Millipore (Billerica, MA). Analytes
detected using DuoSet kits used biotin-
ylated detection antibodies and Alexa
Fluor 647– conjugated streptavidin
(Invitrogen).
One biomarker was measured per
384 microwell plates, using an average of
1.3 l serum in a total assay volume of 10
l/well. Biomarker concentrations were
calculated as the mean of three replicates.
Assays had dynamic ranges of 102–103,
intraplate coefficients of variation of
Table 1—Baseline characteristics of the analyzed subset of the Inter99 cohort
Converters Nonconverters P
Participants 160 472
Male sex 110 (68.8) 279 (59.1) 0.031
NFG and NGT 12 (7.6) 226 (49.7) 0.0001
IFG only 46 (29.1) 174 (38.2) 0.0433
IGT only 25 (15.8) 19 (4.2) 0.0001
Both IFG and IGT 75 (47.5) 36 (7.9) 0.0001
Family history 48 (30.0) 98 (20.8) 0.0223
Age (years) 50.2 (45.2–55.0) 49.8 (44.8–54.8) 0.0001
Height (cm) 172 (166–179) 172 (166–179) 0.9277
Weight (kg) 89 (80–100) 84 (77–93) 0.0001
BMI (kg/m2) 29.7 (27.5–32.9) 27.6 (26.1–30.1) 0.0001
Waist circumference (cm) 97 (91–109) 93 (86–99) 0.0001
Hip circumference (cm) 106 (102–113) 104 (100–109) 0.004
Systolic blood pressure (mmHg) 140 (130–150) 130 (120–144) 0.0001
Diastolic blood pressure (mmHg) 90 (80–96) 85 (80–90) 0.0008
Fasting serum total cholesterol (mmol/l) 5.8 (5.1–6.5) 5.7 (5.0–6.4) 0.2513
Fasting serum HDL cholesterol (mmol/l) 1.2 (1.0–1.4) 1.3 (1.1–1.6) 0.0013
Fasting serum LDL cholesterol (mmol/l) 3.6 (3.1–4.4) 3.6 (3.1–4.3) 0.6898
Fasting serum triglycerides (mmol/l) 1.6 (1.3–2.2) 1.3 (0.9–1.8) 0.0001
Fasting serum insulin (pmol/l) 58 (37–81) 40 (27–59) 0.0001
2-h serum insulin (pmol/l) 325 (210–486) 186 (100–298) 0.0001
FPG (mmol/l) 6.1 (5.7–6.5) 5.6 (5.3–6.0) 0.0001
2-h plasma glucose (mmol/l) 8.4 (7.1–9.5) 6.1 (5.1–7.0) 0.0001
A1C (%) 6.1 (5.8–6.4) 5.9 (5.6–6.1) 0.0001
Adiponectin (g/ml) 19.5 (9.3–39.6) 22.2 (12.9–42.6) 0.0345
CRP (g/ml) 3.2 (1.5–7.9) 2.0 (0.8–5.3) 0.0001
Ferritin (ng/ml) 867 (290–1749) 483 (168–1045) 0.0001
IL-2RA (pg/ml) 290 (230–400) 270 (200–350) 0.0049
Data are n (%) or median (interquartile range) for continuous variables. Data are from 632 subjects in the
subsample of 3,032 at-risk individuals with BMI 25 kg/m2 and age 39 years from the Inter99 cohort.
Converters are individuals who developed epidemiologically defined diabetes within 5 years. Nonconverters
were randomly selected from the Inter99 cohort in an approximately 3:1 ratio to converters. IFG was defined
as FPG of 5.6–6.9 mmol/l. Impaired glucose tolerance (IGT) was defined as 2-h postload glucose of
7.8–11.1 mmol/l. At baseline, 92% of the converters had IFG, IGT, or both, whereas 50% of nonconverters
had IFG, IGT, or both. For categorical descriptors, values are counts (percentage of total for that cohort).
Differences in frequency between converters and nonconverters were evaluated with a Monte Carlo estima-
tion of the 2 statistic (2,000 replicates). Differences in medians were evaluated with a Wilcoxon test. NFG,
normal fasting glucose; NGT, normal glucose tolerance.
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5%, and an average lower limit of de-
tection of 10 pg/ml.
Model development process
We devised a model development process
applying multiple statistical approaches
in which a limited number of the most
informative markers would be selected
for inclusion. Sixty-four candidate bi-
omarkers were evaluated for inclusion in
multimarker models: six routine labora-
tory measures (FPG, fasting serum insu-
lin, triglycerides, total cholesterol, HDL
cholesterol, and LDL cholesterol) and 58
serum proteins. Biomarker candidates
were selected for inclusion in the model
based on frequency of selection in four
statistical learning approaches (for details
see online Appendix B, available at http://
care.diabetesjournals.org/cgi/content/full/
dc08-1935/DC1). We refer to the four
approaches as U (univariate logistic re-
gression analyses), E (exhaustive enu-
meration of small [6] multivariate
logistic models), H (six different heuris-
tic model-building methods, including
forward, backward, and stepwise selec-
tion, Kruskal-Wallis, random forest,
and Eigengene-based linear discriminant
analysis with three different statistical
learning algorithms, including logistic re-
gression, linear discriminant analysis, and
support vector machines), and B (fre-
quency of selection within 100 bootstrap
replicates using the same basic heuristic
model-building methods).
Permutation testing was used to es-
tablish a threshold of selection frequency
for inclusion of a biomarker in the model.
For the permutation testing, the entire se-
lection procedure was repeated using a
dataset with randomly assigned out-
comes. To be included in the model, the
selection frequency of a biomarker in the
dataset with nonpermuted (true) out-
comes had to fall outside the 95% CI of its
selection frequency using the dataset with
randomly assigned outcomes. To make
the model more parsimonious, the bi-
omarkers selected were subjected to
backwards selection, sequentially remov-
ing biomarkers until all remaining bi-
omarkers were significant at the 90%
confidence level.
RESULTS— Baseline characteristics of
converter and nonconverter groups are
summarized in Table 1. The univariate re-
sults for 58 candidate serum biomarkers
for 5-year risk of type 2 diabetes are pre-
sented in online Appendix A.
Applying our model development
process to all 64 candidate biomarkers
(58 serum proteins and 6 routine labora-
tory measures), we found that CRP,
FTH1, glucose, alanine aminotransferase,
and insulin were selected by all four ap-
proaches (U, E, H, and B); IGF binding
protein 2, IL-2RA, and heat shock 70-kDa
protein 1B were selected by three ap-
proaches (E, H, and B); leptin and inter-
leukin 18 (IL-18) were selected by two
approaches (U and E); and ADIPOQ was
selected by one approach (E). After back-
wards selection, the resulting Diabetes
Risk Score (DRS) model included six bi-
omarkers (ADIPOQ, CRP, FTH1, glucose,
IL-2RA, and insulin). The performance of
this model was estimated using the boot-
strap resampling approach. Figure 1 com-
pares the area under the receiver
operating characteristic (ROC) curves for
the fitted performance of this DRS model
to assess 5-year type 2 diabetes risk in the
dataset (area under the curve [AUC] 
0.78) with that of this DRS model using
bootstrap resampling of the dataset
(AUC 0.76). The similarity of the AUCs
suggests that this model is not overfit and
is likely to be robust when used to assess
risk in a different population. A separate
analysis is presented in online Appendix
B, in which the bootstrap resampling ap-
proach to model validation was compared
with an approach that used training and
validation data subsets. The similarity in
performance between the bootstrap esti-
mate of performance on the training set
and performance on a sequestered valida-
tion dataset validates use of the bootstrap
approach to estimate model performance.
Figure 2 compares the AUC of this
DRS model with that of several routine
laboratory measures (A1C, FPG, fasting
serum insulin, 2-h serum insulin, and 2-h
plasma glucose from the OGTT), two
clinical variables (BMI and sex-adjusted
waist circumference), a model using fast-
ing glucose and insulin, and a noninva-
sive clinical model (age, BMI, waist
circumference, and family history of type
2 diabetes in first-degree relatives). The
AUC of this DRS model is statistically sig-
nificantly different from that of single
marker measures from fasting blood sam-
ples, a model using fasting glucose and
insulin, anthropometric measures, and a
clinical index, whereas it is equivalent to
2-h glucose (from OGTT) and 2-h insulin
(P  0.18 and P  0.70, respectively).
Adding family history, age, BMI, and
waist circumference components of the
noninvasive model to this DRS model im-
proved the fit slightly (P  0.0067, like-
Figure 1—Performance and validation of a model to assess risk of 5-year incidence of type 2
diabetes in the Inter99 cohort. Shown are ROC curves for a model that uses the levels of six
biomarkers (fasting serumADIPOQ, CRP, insulin, FTH1, and IL-2RA and fasting plasma glucose)
that was developed using the entire dataset (all 632 converters and nonconverters, blue line) and
validated using a bootstrap resampling approach (red dashed line).
Kolberg and Associates
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lihood ratio test) but produced only a
marginal performance gain (AUC 0.792
vs. 0.780, P  0.059). It should also be
noted that the DRS average for women is
1.35 lower than that for men (P 
0.0001). However, this sex difference ac-
curately reflects the difference in risk of
developing diabetes, and the performance
of the DRS is equivalent in both sexes
(AUC 0.770 and 0.783 for women and
men, respectively; P  0.7908).
To extrapolate results from this
nested case-control study to the entire at-
risk population within the Inter99 cohort
and to provide a way to convert a DRS to
the absolute risk of developing diabetes
for an individual, Bayes’ law was applied
to adjust for the observed 5.7% 5-year
rate of conversion to diabetes for the pop-
ulation with BMI 25 kg/m2 and age
39 years (see online Appendix C).
Figure 3 compares the stratification of
risk achieved by measuring FPG and 2-h
glucose to that achieved using this DRS
model. Figure 3A shows that the DRS pro-
vides a continuous measure of risk of pro-
gression to type 2 diabetes in the at-risk
population. Figure 3B illustrates the risk
level by FPG class, using the threshold of
100 mg/dl for IFG. The IFG group has a
5-year conversion risk, which is 1.4-fold
higher than the pretest probability, and
comprises 56% of the at-risk population.
Figure 3C illustrates the level of risk in
each stratum when this DRS is used to
stratify the individuals into low-, medi-
um-, and high-risk groups. Individuals in
the high-risk group have a 3.5-fold in-
creased risk over the pretest probability
and comprise 10% of the population. In-
dividuals in the low-risk group have a
3.5-fold lower risk and comprise 54% of
the population, and the remaining medi-
um-risk group has a 1.3-fold increased
risk and comprises 36% of the popula-
tion. As might be expected from the AUC
comparison, the risk of development of
diabetes in subjects with impaired glu-
cose tolerance (14.6% of the population)
is 24.5%, which is similar to the risk in the
high-risk DRS group. Yet, the low-risk
group identified by DRS has a 1.6% risk of
developing diabetes, which is lower than
that of subjects with either normal fasting
glucose (2.4%) or normal glucose toler-
ance (2.5%) in this study.
CONCLUSIONS— Previous efforts
to identify biomarkers that might be use-
ful in assessing risk of type 2 diabetes have
evaluated a limited number of candidates.
We sought to explore the predictive
power of many molecules in a variety of
biological pathways that are known to be
altered in diabetes, in addition to glucose
homeostasis pathways, hypothesizing
that any molecule involved in the patho-
physiology of diabetes might provide ad-
ditional predictive power. The molecular
counting technology assay platform, with
its small sample volume requirements,
permitted the quantitative analysis of
many more protein markers than have
previously been analyzed in a single
study.
The current methods of assessing
type 2 diabetes risk are inconvenient,
have logistical challenges to implementa-
tion, and have poor specificity. A multibi-
omarker model was developed to assess
risk of type 2 diabetes by selecting bio-
markers using multiple statistical ap-
proaches. The performance of this DRS
model is better than that of any other
baseline measure of risk and is similar to
2-h glucose levels in an OGTT, a test that
is rarely used because of its inconve-
nience. This DRS identifies high-risk in-
dividuals with a four times increased risk
of developing diabetes, who comprise
10% of the population, and low-risk in-
dividuals, who comprise 50% of the
population (Fig. 3C). This DRS model
provides a more convenient alternative
for obtaining a quantitative risk estimate:
a laboratory would measure the biomar-
ker concentrations in a fasting blood sam-
ple and return the computed risk score.
This DRS model does not depend on an-
thropometrics or self-reported risk factors
(such as family history or tobacco use).
The six biomarkers selected for this
DRS model are involved in various bio-
logical pathways. Ferritin serves as an an-
tioxidant by binding excess iron, and
elevated serum ferritin is a well-established
risk factor for future type 2 diabetes (15).
Glucose and insulin are critical indicators
of metabolic disorders including diabetes
and obesity. Adiponectin is involved in
the metabolic syndrome and inflamma-
tion, and decreased serum adiponectin is
a known risk factor for type 2 diabetes
(19). CRP and IL-2RA are also involved in
inflammatory pathways. Although the as-
sociation of CRP levels with type 2 diabe-
tes risk has been reported previously
(13,20), this is the first study to our
knowledge that implicates serum IL-2RA
levels in type 2 diabetes risk. In diabetes,
effective serum insulin levels are low,
whereas levels of circulating glucose and
free fatty acids are high, creating an envi-
ronment of oxidative stress. Such oxida-
tive stress activates inflammatory
pathways and ultimately activates T lym-
phocytes (21). At least one study reported
an increase in activated T lymphocytes in
Figure 2—ROCanalyses for 11methods of assessing 5-year risk for type 2 diabetes. DRS, diabetes
risk score developed in the present study; HOMA-IR, (fasting serum insulin  fasting plasma
glucose)/22.5; noninvasive clinical model, a noninvasive clinical algorithm using age, BMI, waist
circumference, and family history in a first-degree relative); OGTT, 2-h oral glucose tolerance
test. ***P  0  0.001; **P  0.001 to 0.01.
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patients with type 2 diabetes who were
hospitalized for diabetic ketoacidosis
(22). Because IL-2RA is upregulated upon
T lymphocyte activation, it is possible that
increased serum IL-2RA is an indicator of
increased levels of activated T-cells.
Because Inter99 was an intervention
study, it is possible that the performance
of this DRS model observed is lower than
might be expected in an observational
study. In the Inter99 study, interventions
showed small but distinct effects on
smoking (23), physical activity (24), and
diet (25), although the 5-year conversion
rate in this population was similar to that
in other populations that did not partici-
pate in lifestyle interventions. Any impact
of the lifestyle changes on the outcomes in
the Inter99 study would not be reflected
in the baseline biomarker measurements,
which should have made it more difficult
to discriminate between those who pro-
gressed to type 2 diabetes versus those
who did not. In an observational study, it
is possible that this DRS model might pro-
vide even greater discrimination between
those at high versus low risk. The robust
performance of the model in an interven-
tional study further strengthens our
findings.
In summary, by applying a variety of
statistical methods for biomarker selec-
tion we developed a DRS model that in-
corporates six circulating biomarkers. A
development process was designed to
generate a model that is likely to be gen-
eralizable to other populations. This DRS
provides superior assessment of diabetes
risk compared with fasting plasma glu-
cose alone. In this study, 50% of the
subjects had IFG with a risk of developing
diabetes only 1.4 times greater than the
general population rate. Because this
study was limited to overweight middle-
aged white individuals, it will be impor-
tant to replicate these findings in other
populations. However, the current results
suggest this DRS could be an important
tool for identifying the individuals at
highest risk of developing type 2 diabetes,
a population for whom the most compre-
hensive prevention strategies should be
considered. The improved performance of
this model compared with that of single
markers demonstrates the value of risk as-
sessment models that incorporate multiple
biomarkers from diverse pathophysiologi-
cal pathways associated with type 2
diabetes.
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